EUVIMEDEUVIMED entdecken
Crossref

Polypharmacy and Antibody Response to SARS-CoV-2 Vaccination in Residents of Long-Term Care Facilities: The GeroCovid Vax Study

Caterina Trevisan, Labjona Haxhiaj iD, Alba Malara, Angela Abbatecola, Giorgio Fedele, Annapina Palmieri, Pasqualina Leone, Ilaria Schiavoni, Paola Stefanelli, Stefania Maggi, Giuseppe Sergi, Stefano Volpato und 3 weitere

Drugs & Aging · 2023-12 · 40 (12) · 1133-1141

DOI: 10.1007/s40266-023-01075-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drugs & Aging, online erschienen am 08.11.2023. Verfasst von Caterina Trevisan und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Sciences, University of Ferrara, Ferrara, Italy. Hauptthemen laut MEDLINE: COVID-19 Vaccines, COVID-19. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: Agenzia Italiana del Farmaco, Ministero della Salute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND AND OBJECTIVE: Polypharmacy is common in older adults, particularly among those living in long-term care facilities. This condition represents a marker of clinical complexity and might directly affect the immunological response. However, there are limited data on the association of polypharmacy with vaccine immunogenicity. This study evaluated the immune response to anti-SARS-CoV-2 vaccines in older residents of long-term care facilities as a function of the number of medications used. METHODS: In 478 long-term care facility residents participating in the GeroCovid Vax study, we assessed SARS-CoV-2 trimeric S IgG levels through chemiluminescent assays before the vaccination and after 2, 6, and 12 months. A booster dose was administered between 6- and 12-month assessments. Sociodemographic information and data on chronic diseases and medications were derived from medical records. Based on the number of daily medications, residents were classified into the no polypharmacy (zero to four medications), polypharmacy (five to nine medications), and hyperpolypharmacy (ten or more medications) groups. RESULTS: In the sample (mean age 82.1 years, 69.2% female), 200 (41.8%) residents were taking five or fewer medications/day (no polypharmacy), 229 (47.9%) had polypharmacy, and 49 (10.3%) had hyperpolypharmacy. Using linear mixed models adjusted for potential confounders, we found that hyperpolypharmacy was associated with a steeper antibody decline after 6 months from the first vaccine dose administration (β = - 0.29, 95% confidence interval - 0.54, - 0.03, p = 0.03) than no polypharmacy, while no significant differences were observed at 12 months. CONCLUSIONS: The humoral immune response to SARS-CoV-2 vaccination of older residents showed only slight changes as a function of the number of medications taken. Although it seemed less durable among older residents with hyperpolypharmacy, the booster dose administration equalized such a difference.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19 VaccinesCOVID-19HumansFemaleAgedAged, 80 and overMaleSARS-CoV-2Long-Term CarePolypharmacyAntibody FormationVaccination

Substanzen

COVID-19 Vaccines

Autor:innen und Institutionen

  • Department of Medical Sciences, University of Ferrara, Ferrara, Italy.
  • Department of Neurobiology, Care Sciences and Society, Aging Research Center, Karolinska Institutet and Stockholm University, Stockholm, Sweden.
  • Department of Medicine, University of Padua, Via Giustiniani 2, 35128, Padua, Italy.
  • Department of Medicine, University of Padua, Via Giustiniani 2, 35128, Padua, Italy. labjona92@gmail.com.
  • ANASTE Humanitas Foundation, Rome, Italy.
  • Alzheimer's Disease Day Clinic, Azienda Sanitaria Locale, Frosinone, Italy.

ORCID-Profile: Labjona Haxhiaj

Förderung

  • Agenzia Italiana del Farmaco, Ministero della Salute

Zitieren

APA

Trevisan, C., Haxhiaj, L., Malara, A., Abbatecola, A., Fedele, G., Palmieri, A., Leone, P., Schiavoni, I., Stefanelli, P., Maggi, S., Sergi, G., Volpato, S., Incalzi, R. A., Onder, G., & GeroCovid Vax Working Group (2023). Polypharmacy and Antibody Response to SARS-CoV-2 Vaccination in Residents of Long-Term Care Facilities: The GeroCovid Vax Study. Drugs & Aging, 40(12), 1133-1141. https://doi.org/10.1007/s40266-023-01075-9

Vancouver

Trevisan C, Haxhiaj L, Malara A, Abbatecola A, Fedele G, Palmieri A, et al. Polypharmacy and Antibody Response to SARS-CoV-2 Vaccination in Residents of Long-Term Care Facilities: The GeroCovid Vax Study. Drugs & Aging. 2023;40(12):1133-1141. doi:10.1007/s40266-023-01075-9

BibTeX
@article{Trevisan2023,
  author = {Trevisan, Caterina and Haxhiaj, Labjona and Malara, Alba and Abbatecola, Angela and Fedele, Giorgio and Palmieri, Annapina and Leone, Pasqualina and Schiavoni, Ilaria and Stefanelli, Paola and Maggi, Stefania and Sergi, Giuseppe and Volpato, Stefano and Incalzi, Raffaele Antonelli and Onder, Graziano and GeroCovid Vax Working Group, GeroCovid Vax Working Group},
  title = {Polypharmacy and Antibody Response to SARS-CoV-2 Vaccination in Residents of Long-Term Care Facilities: The GeroCovid Vax Study},
  journal = {Drugs & Aging},
  year = {2023},
  volume = {40},
  number = {12},
  pages = {1133--1141},
  doi = {10.1007/s40266-023-01075-9}
}
Kostenlos starten →